This is a preview of subscription content, log in via an institution to check access.
Notes
2014 US dollars
Reference
Goldstein DA, et al. Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost. 51st Annual Meeting of the American Society of Clinical Oncology : abstr. 6505, 29 May 2015. Available from: URL: http://abstracts.asco.org/156/AbstView_156_148067.html
Rights and permissions
About this article
Cite this article
Necitumumab in NSCLC: value-based pricing. PharmacoEcon Outcomes News 732, 23 (2015). https://doi.org/10.1007/s40274-015-2289-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2289-1